Filing summary
Entity and period: The filing is Ikena Oncology, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2021, not Imagenebio, Inc. The company is a development-stage targeted oncology business with no approved products and no product-sales revenue.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Collaboration revenue | $3.7 million | $2.8 million | $10.8 million | $9.1 million |
| Research and development expense | $13.4 million | $7.2 million | $34.8 million | $21.4 million |
| General and administrative expense | $4.9 million | $1.8 million | $12.9 million | $6.2 million |
| Net loss | $14.5 million | $6.2 million | $36.9 million | $18.2 million |
| Net loss per share, basic and diluted | $0.40 | $2.34 | $1.46 | $6.85 |
Revenue came from the BMS collaboration and represents research and development services, not product sales. The company reported no gross margin. At September 30, 2021, cash and cash equivalents were $245.9 million, total current assets were $251.9 million, current liabilities were $30.6 million, and total liabilities were $58.4 million. The balance sheet reports no debt. Nine-month operating cash use was $46.9 million; investing cash use was $1.2 million; financing cash provided was $131.5 million, primarily from the IPO. Accumulated deficit was $148.3 million.
Changes versus comparable periods
- Q3 collaboration revenue rose 32%, while total operating expenses increased 102% and net loss widened 133% year over year.
- For the first nine months, collaboration revenue increased 18%, operating expenses rose 73%, and net loss more than doubled.
- Higher R&D spending reflected IK-930 IND-enabling, manufacturing and trial start-up work; IK-412 development; and expanded discovery programs and staffing. Lower IK-007 spending partly offset the increases.
- G&A growth reflected higher headcount, insurance, and public-company legal, audit, consulting and facilities costs.
- The March 2021 IPO generated approximately $131.3 million in net proceeds. Preferred shares converted into common stock at the IPO.
Outlook, commentary and risks
- Management said September-end cash was expected to fund operating expenses and capital expenditures through 2023, while cautioning that actual cash needs could be higher and additional funding may be required.
- IK-930’s IND was accepted by the FDA in October 2021, after quarter-end; the company planned to begin its first-in-human trial in Q1 2022. Multiple RAS-pathway development candidates were expected over the following 18 months.
- COVID-19-related competition for a manufacturing component delayed IK-412 supply and its IND timeline. The company also relies on third-party manufacturers and CROs, including single-source API suppliers.
- The BMS agreement covers IK-175 and IK-412. Ikena performs research and development through Phase 1b, with BMS holding license options. Ikena may receive option exercise payments, milestone payments and royalties if the options are exercised and products progress or achieve sales.
- Key risks include clinical and regulatory failure, biomarker-defined patient enrollment and market-size uncertainty, manufacturing and supply disruption, dependence on collaborators, competition, intellectual-property challenges, and the need for further capital. The company has no committed external funding source.
- No material litigation was reported. Management stated disclosure controls were effective at the reasonable-assurance level and reported no material change in internal control over financial reporting.
Important facts to verify
- Confirm the filing issuer: the supplied document is for Ikena Oncology, Inc., although the request metadata names Imagenebio, Inc.
- Check subsequent disclosures for IK-930 trial initiation and IK-412’s revised IND and manufacturing schedule.
- Assess cash burn against the stated through-2023 runway, particularly as clinical and discovery spending expands.
- Review BMS option status, remaining collaboration obligations, and the timing and conditions of potential payments.
- Track clinical progress, enrollment, safety findings and supply availability for IK-175, IK-007 and other programs.